CorPath® telerobotic interventional platform
has the potential to deliver timely, specialized cardiovascular
treatment to remote, underserved patient populations across the
globe.
KEY TAKEAWAYS
Corindus’ telerobotic coronary interventional platform has the
potential to:
- Dramatically improve patient access for
both elective and emergent percutaneous coronary interventions in
rural and underserved populations
- Reduce time to treatment for emergent
procedures such as STEMI
- Reduce variability in operator skills,
and thus improve clinical outcomes
- Expand to other indications to address
stroke care
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a
leading developer of precision vascular robotics, announces that
its CorPath technology was used to conduct the first-in-human (FIH)
Telerobotic Intervention Study, December 4 and 5, 2018, in India.
This study represents the world’s first percutaneous coronary
intervention (PCI) conducted from a remote location outside of the
catherization lab. Five patients located at the Apex Heart
Institute in Ahmedabad, Gujarat, underwent an elective PCI
procedure from a distance of roughly 20 miles (32 km) away. Each
procedure was remotely performed by internationally acclaimed
physician, Dr. Tejas Patel, Chairman and Chief Interventional
Cardiologist of the Apex Heart Institute, from inside the
Swaminarayan Akshardham temple located in Gandhinagar. His partner,
Dr. Sanjay Shah, was in the room with the patient at the Apex Heart
Institute. The success of this study paves the way for large-scale,
long-distance telerobotic platforms across the globe.
“The first in human cases of remote robotic PCI represent a
landmark event for interventional medicine,” stated Dr. Patel. “The
application of telerobotics in India has the potential to impact a
significant number of lives by providing access to care that may
not otherwise have been possible. For the first time in
cardiology’s history, India will shine for this ground-breaking
innovation, and I am honored to be a part of this historic
occasion.”
Cardiovascular disease, including stroke, is the number one
cause of death worldwide resulting in nearly 18 million deaths per
year. Geographic barriers, socioeconomic status and a rapidly
shrinking number of skilled specialists significantly hinder
patient access to timely, specialized cardiovascular care. This is
especially of concern during highly emergent medical events, such
as heart attack and stroke, where ideally treatment is received in
as little as 90 minutes or within 24 hours, respectively, to avoid
death or permanent disability.
To improve patient outcomes, Corindus has pioneered the world’s
first remote telerobotic interventional platform to deliver highly
specialized and timely cardiovascular care to underserved patient
populations with geographic barriers to treatment. Following the
successful FIH telerobotic coronary stenting cases performed in
India, the company plans to begin commercial product development
for use of the CorPath System in remote interventions and expand
the company’s robotic platform to address stroke care.
Mark Toland, President and Chief Executive Officer of Corindus,
stated, “Cardiovascular disease, including stroke, is the world’s
most significant and undertreated clinical problem due to limited
access to specialized, timely medical care. As a result of existing
barriers to care, including increased global poverty and a
declining number of trained specialists, only a fraction of
patients worldwide receives life-saving treatment, resulting in
substantial death or disability. We anticipate that our technology
will revolutionize cardiovascular disease treatment by providing
specialized and timely medical care to anyone, anywhere.”
In September 2018, at the Transcatheter Cardiovascular
Therapeutics (TCT) Conference in San Diego, the first live
transmission of a remote robotic demonstration was streamed from
Mayo Clinic using CorPath GRX with developmental remote technology
in a porcine model. Recently the Mayo Clinic received a multi-year
$3.3 million grant from The Leona M. and Harry B. Helmsley
Charitable Trust to support exploring the feasibility and
practicality of using remote robotic technology for cardiac
interventions. Mr. Walter Panzirer, trustee of the Helmsley
Charitable Trust, was in attendance for the FIH telerobotic study
in India. “We are excited to see the next step successfully
completed, which demonstrates cardiologists can safely operate
remotely on patients,” said Panzirer. “This gets us one step closer
to realizing our vision that rural populations can get
time-sensitive cardiac interventions sooner, ultimately saving
lives.”
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader
in robotic-assisted vascular interventions. The company's CorPath®
System is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and vascular procedures. During
the procedure, the interventional cardiologist sits at a
radiation-shielded workstation to advance guide catheters, stents,
and guidewires with millimeter-by-millimeter precision. The
workstation allows the physician greater control and the freedom
from wearing heavy lead protective equipment that causes
musculoskeletal injuries. CorPath GRX is the second generation
robotic-assisted technology offering enhancements to the platform
by adding important key upgrades that increase precision, improve
workflow, and extend the capabilities and range of procedures that
can be performed robotically. With the CorPath System, Corindus
Vascular Robotics brings robotic precision to interventional
procedures to help optimize clinical outcomes and minimize the
costs associated with complications of improper stent placement
during manual procedures. For additional information, visit
www.corindus.com, and follow @CorindusInc.
About Dr. Tejas Patel and Apex Heart Institute
Dr. Tejas Patel is Chief Interventional Cardiologist and
Chairman of Apex Heart Institute. He has been awarded Padma Shri by
the Government of India for his contribution in coronary
intervention. Apex Heart Institute is a center of excellence for
cardiac ailments with two ultra-modern cath labs and two state of
the art cardiac surgical theatres. It has 85 beds comprised of 3
medical ICUs, 2 surgical ICUs, 1 HDU, a general ward and rooms in
various categories. The institution has an outstanding team of
doctors, who ensure delivery of quality care with highest level of
expertise. At Apex Heart Institute, well-trained paramedical staff,
world class infrastructure, efficient systems and processes ensure
effective services aiding to speedy recoveries. The institution has
instituted TRICO (Transradial Intervention Course) by leveraging
the knowledge and practices of world renowned interventional
cardiologists, which today is the largest and the most popular
radial course in the world. https://www.apexheart.in/
About Swaminarayan Akshardham:
Swaminarayan Akshardham is India’s iconic temple that celebrates
ancient art and architecture, culture and spirituality, wisdom and
values. Inspired and created by HH Pramukh Swami Maharaj in 1992,
the Cultural Complex is spread over 23 acres and was built by more
than 8 million volunteer hours of selfless service. Visited by more
than 57 million visitors from 127 countries across the world, the
Swaminarayan Akshardham complex consists of an intricately carved
inner-sanctum Mandir, exhibition halls, Abhishek Mandapam and one
of its kind Sat-Chit-Anand water show. It is overseen by HH Mahant
Swami Maharaj, the present spiritual leader of BAPS Swaminarayan
Sanstha, which is an international socio-spiritual charitable NGO,
affiliated to the United Nations, that serves society through over
160 humanitarian services at its 1,200 temples and 4,000
centres.
Forward Looking Statements
Statements made in this release that are not statements of
historical or current facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Corindus to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on
any forward-looking statements. In addition to statements that
explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects,"
"estimates," "intends," "anticipates" or "plans" to be uncertain
and forward-looking. Forward-looking statements may include
comments as to Corindus’ beliefs and expectations as to future
events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside Corindus’
control.
Examples of such statements include statements regarding or such
as:
- the ability of the CorPath telerobotic
interventional platform to deliver timely, specialized
cardiovascular treatment to remote, underserved patient populations
across the globe;
- the success of the FIH studies paving
the way for large-scale, long distance telerobotic platforms across
the globe;
- the advancement of our remote vascular
robotic technology;
- plans to begin commercial development
for the system;
- the expansion of Corindus’
interventional platform into stroke treatment; and
- the potential for remote vascular
robotic technology to revolutionize treatment times for patients
suffering from stroke and heart attacks.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are described in the sections titled "Risk Factors" in the
Company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, including,
but not limited to the following: our ability to expand our
technology platform and achieve the advances necessary for
telestenting and remote procedures, including in humans; our
ability to expand our technology platform for use in other segments
of the vascular intervention market, including neurointerventional
and other more complex cardiac interventions; obtaining necessary
regulatory approvals for the use on humans and marketing of our
products in the United States and in other countries; risks
associated with market acceptance; our ability to enforce our
intellectual property rights; our need for additional funds to
support our operations; factors relating to engineering,
regulatory, manufacturing, sales and customer service challenges;
and potential safety and regulatory issues that could slow or
suspend our sales. Forward looking statements speak only as of the
date they are made. Corindus undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise that occur
after that date. More information is available on Corindus' website
at http://www.corindus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181206005067/en/
Media Contact:Trevi CommunicationsLisa MurrayT:
978-750-0333 ext. 2lisa@trevicomm.com
Investor Relations Contact:Lisa WilsonIn-Site
Communications, Inc.T: 917-543-9932ir@corindus.com
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jul 2023 to Jul 2024